Announcements Trials

Browse Landscape

Phase

Status

Recruiting 23 Active not recruiting 8 Completed 3 Withdrawn 1 Terminated 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 4 Colorectal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Triple Negative Breast Neoplasms 1 Squamous Non-small Cell Lung Cancer 1 Pancreatic Neoplasms 1 Melanoma 1 Liver Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Hepatocellular 1 Biliary Tract Neoplasms 1 Adenocarcinoma Of Esophagus 1

Interventions

Sorafenib 13 Radiosurgery 9 spartalizumab 7 lenvatinib 7 Oxaliplatin 6 Gemcitabine 5 Fluorouracil 5 Radiotherapy 4 Cisplatin 4 Bevacizumab 4 atezolizumab 3 Leucovorin 3 Folfox protocol 3 Doxorubicin 3 gadolinium ethoxybenzyl DTPA 2 fludarabine 2 cabozantinib 2 Nivolumab 2 Mitomycin 2 Electroporation 2 Cyclophosphamide 2 Chemoembolization, Therapeutic 2 tremelimumab 1 toripalimab 1 tocilizumab 1 tislelizumab 1 temsirolimus 1 tazemetostat 1 sitravatinib 1 pirarubicin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Carcinoma, Hepatocellular × tremelimumab × Clear all

NCT06994299 2025-11-18

PRISM

Weill Medical College of Cornell University

Phase 2 Withdrawn

Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡